In a new commentary for, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. Included in Jackie’s list are launching with a weak payer value message, failing to make a data-driven economic argument for access, and overlooking the pull-through challenge.

To read her commentary, please click here.